Advertisement

Hypoxic expression of NLRP3 and VEGF in cultured retinal pigment epithelial cells: contribution of P2Y2 receptor signaling

  • Fabian Doktor
  • Philipp Prager
  • Peter Wiedemann
  • Leon Kohen
  • Andreas Bringmann
  • Margrit Hollborn
Original Article

Abstract

Retinal hypoxia is a major condition of the chronic inflammatory disease age-related macular degeneration. Extracellular ATP is a danger signal which is known to activate the NLRP3 inflammasome in various cell systems. We investigated in cultured human retinal pigment epithelial (RPE) cells whether hypoxia alters the expression of inflammasome-associated genes and whether purinergic receptor signaling contributes to the hypoxic expression of key inflammatory (NLRP3) and angiogenic factor (VEGF) genes. Hypoxia and chemical hypoxia were induced by a 0.2%-O2 atmosphere and addition of CoCl2, respectively. Gene expression was determined with real-time RT-PCR. Cytosolic NLRP3 and (pro-) IL-1β levels, and the extracellular VEGF level, were evaluated with Western blot and ELISA analyses. Cell culture in 0.2% O2 induced expression of NLRP3 and pro-IL-1β genes but not of the pro-IL-18 gene. Hypoxia also increased the cytosolic levels of NLRP3 and (pro-) IL-1β proteins. Inflammasome activation by lysosomal destabilization decreased the cell viability under hypoxic, but not control conditions. In addition to activation of IL-1 receptors, purinergic receptor signaling mediated by a pannexin-dependent release of ATP and a release of adenosine, and activation of P2Y2 and adenosine A1 receptors, was required for the full hypoxic expression of the NLRP3 gene. P2Y2 (but not A1) receptor signaling also contributed to the hypoxic expression and secretion of VEGF. The data indicate that hypoxia induces priming and activation of the NLRP3 inflammasome in cultured RPE cells. The hypoxic NLRP3 and VEGF gene expression and the secretion of VEGF are in part mediated by P2Y2 receptor signaling.

Keywords

Retinal pigment epithelium P2Y2 NLRP3 VEGF Inflammasome Hypoxia 

Abbreviations

AIM

absent in melanoma

AMD

age-related macular degeneration

AOPCP

adenosine-5′-O-(α,β-methylene)-diphosphate

AP

activator protein

ASC

apoptosis-associated speck-like protein containing a caspase-recruitment domain

ATP

adenosine 5′-triphosphate

CAPE

caffeic acid phenethyl ester

CREB

cAMP response element-binding protein

DPCPX

8-cyclopentyl-1,3-dipropylxanthine

HIF

hypoxia-inducible transcription factor

IL

interleukin

NFAT

nuclear factor of activated T cell

NLRC

NLR family CARD domain-containing protein

NLRP

nucleotide-binding oligomerization domain receptors-like receptor protein

RPE

retinal pigment epithelium

siRNA

small interfering RNA

STAT

signal transducer and activator of transcription

VEGF

vascular endothelial growth factor

Notes

Acknowledgments

The authors thank Ute Weinbrecht for excellent technical assistance.

Authors’ contribution

LK, AB, and MH conceived and designed the experiments. FD, PP, and MH performed the experiments. FD, AB, and MH analyzed and interpreted the data. PW, LK, and MH supervised research personnel. FD, AB, and MH drafted the manuscript. PW and LK made critical revision of the manuscript. All authors read and approved the final manuscript.

Funding information

This research was supported by grants from the Deutsche Forschungsgemeinschaft (KO 1547/7-1 to L.K.) and the Geschwister Freter Stiftung (Hannover, Germany) to P.W.

Compliance with ethical standards

Conflict of interest

Fabian Doktor declares that he has no conflict of interest.

Philipp Prager declares that he has no conflict of interest.

Peter Wiedemann declares that he has no conflict of interest.

Leon Kohen declares that he has no conflict of interest.

Andreas Bringmann declares that he has no conflict of interest.

Margrit Hollborn declares that she has no conflict of interest.

Ethical approval

All experimental protocols in this study were approved by the Ethics Committee of the University of Leipzig (approval #745, 07/25/2011).

References

  1. 1.
    Van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT (2003) Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 18(9):845–854CrossRefGoogle Scholar
  2. 2.
    Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE (2007) Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 114(2):253–262CrossRefGoogle Scholar
  3. 3.
    Gehrs KM, Anderson DH, Johnson LV, Hageman GS (2006) Age-related macular degeneration – emerging pathogenetic and therapeutic concepts. Ann Med 38(7):450–471CrossRefGoogle Scholar
  4. 4.
    Dallinger S, Findl O, Strenn K, Eichler HG, Wolzt M, Schmetterer L (1998) Age dependence of choroidal blood flow. J Am Geriatr Soc 46(4):484–487CrossRefGoogle Scholar
  5. 5.
    Ehrlich R, Kheradiya NS, Winston DM, Moore DB, Wirostko B, Harris A (2009) Age-related ocular vascular changes. Graefes Arch Clin Exp Ophthalmol 247(5):583–591CrossRefGoogle Scholar
  6. 6.
    Kaarniranta K, Sinha D, Blasiak J, Kauppinen A, Vereb Z, Salminen A, Boulton ME, Petrovski G (2013) Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration. Autophagy 9(7):973–984CrossRefGoogle Scholar
  7. 7.
    Ferrington DA, Sinha D, Kaarniranta K (2016) Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration. Prog Retin Eye Res 51:69–89CrossRefGoogle Scholar
  8. 8.
    Feeney-Burns L, Berman ER, Rothman H (1980) Lipofuscin of human retinal pigment epithelium. Am J Ophthalmol 90(6):783–791CrossRefGoogle Scholar
  9. 9.
    Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134(3):411–431CrossRefGoogle Scholar
  10. 10.
    Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242(1):91–101CrossRefGoogle Scholar
  11. 11.
    Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22(1):1–29CrossRefGoogle Scholar
  12. 12.
    Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H (1997) Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 235(3):159–167CrossRefGoogle Scholar
  13. 13.
    Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging retina. Prog Retin Eye Res 28(5):348–368CrossRefGoogle Scholar
  14. 14.
    Cheung CM, Wong TY (2014) Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. J Intern Med 276(2):140–153CrossRefGoogle Scholar
  15. 15.
    Nita M, Grzybowski A, Ascaso FJ, Huerva V (2014) Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation). Mediat Inflamm 2014:930671CrossRefGoogle Scholar
  16. 16.
    Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K (2016) Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 73(9):1765–1786CrossRefGoogle Scholar
  17. 17.
    Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13(6):397–411CrossRefGoogle Scholar
  18. 18.
    Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D'Amore PA, Ksander BR (2013) NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 54(1):110–120CrossRefGoogle Scholar
  19. 19.
    Kerur N, Hirano Y, Tarallo V, Fowler BJ, Bastos-Carvalho A, Yasuma T, Yasuma R, Kim Y, Hinton DR, Kirschning CJ, Gelfand BD, Ambati J (2013) TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci 54(12):7395–7401CrossRefGoogle Scholar
  20. 20.
    Marneros AG (2013) NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration. Cell Rep 4(5):945–958CrossRefGoogle Scholar
  21. 21.
    Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, Amarnath S, Fowler DH, Radwan M, Young MT, Pittman K, Kubes P, Agarwal HK, Parang K, Hinton DR, Bastos-Carvalho A, Li S, Yasuma T, Mizutani T, Yasuma R, Wright C, Ambati J (2014) Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 346(6212):1000–1003CrossRefGoogle Scholar
  22. 22.
    Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC, O'Neill LA, Hollyfield JG, Humphries P (2012) NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18(5):791–798CrossRefGoogle Scholar
  23. 23.
    Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, Kaarniranta K (2012) Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells – implications for age-related macular degeneration (AMD). Immunol Lett 147(1–2):29–33CrossRefGoogle Scholar
  24. 24.
    Anderson OA, Finkelstein A, Shima DT (2013) A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 inflammasome. PLoS One 8(6):e67263CrossRefGoogle Scholar
  25. 25.
    Brandstetter C, Mohr LK, Latz E, Holz FG, Krohne TU (2015) Light induces NLRP3 inflammasome activation in retinal pigment epithelial cells via lipofuscin-mediated photooxidative damage. J Mol Med (Berl) 93(8):905–916CrossRefGoogle Scholar
  26. 26.
    Prager P, Hollborn M, Steffen A, Wiedemann P, Kohen L, Bringmann A (2016) P2Y1 receptor signaling contributes to high salt-induced priming of the NLRP3 inflammasome in retinal pigment epithelial cells. PLoS One 11(10):e0165653CrossRefGoogle Scholar
  27. 27.
    Klein R, Klein BE, Tomany SC, Cruickshanks KJ (2003) The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 110(6):1273–1280CrossRefGoogle Scholar
  28. 28.
    Van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT (2003) Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 44(9):3771–3777CrossRefGoogle Scholar
  29. 29.
    Lifton RP, Gharavi AG, Geller DS (2001) Molecular mechanisms of human hypertension. Cell 104(4):545–556CrossRefGoogle Scholar
  30. 30.
    Reichenbach A, Bringmann A (2016) Purinergic signaling in retinal degeneration and regeneration. Neuropharmacology 104:194–211CrossRefGoogle Scholar
  31. 31.
    Chen R, Hollborn M, Grosche A, Reichenbach A, Wiedemann P, Bringmann A, Kohen L (2014) Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in retinal pigment epithelial cells. Mol Vis 20:242–258PubMedPubMedCentralGoogle Scholar
  32. 32.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25(4):402–408CrossRefGoogle Scholar
  33. 33.
    An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392(6674):405–408CrossRefGoogle Scholar
  34. 34.
    Thiele DL, Lipsky PE (1990) The action of leucyl-leucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptidase I-mediated conversion to membranolytic products. J Exp Med 172(1):183–194CrossRefGoogle Scholar
  35. 35.
    Mohr LK, Hoffmann AV, Brandstetter C, Holz FG, Krohne TU (2015) Effects of inflammasome activation on secretion of inflammatory cytokines and vascular endothelial growth factor by retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 56(11):6404–6413CrossRefGoogle Scholar
  36. 36.
    Lee K, Lee JH, Boovanahalli SK, Jin Y, Lee M, Jin X, Kim JH, Hong YS, Lee JJ (2007) (Aryloxyacetylamino) benzoic acid analogues: a new class of hypoxia-inducible factor-1 inhibitors. J Med Chem 50(7):1675–1684CrossRefGoogle Scholar
  37. 37.
    Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13(11):1235–1242CrossRefGoogle Scholar
  38. 38.
    Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc Natl Acad Sci U S A 93(17):9090–9095CrossRefGoogle Scholar
  39. 39.
    Bours MJ, Dagnelie PC, Giuliani AL, Wesselius A, Di Virgilio F (2011) P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. Front Biosci (Schol Ed) 3:1443–1456Google Scholar
  40. 40.
    Housley GD, Bringmann A, Reichenbach A (2009) Purinergic signaling in special senses. Trends Neurosci 32:128–141CrossRefGoogle Scholar
  41. 41.
    Shi G, Chen S, Wandu WS, Ogbeifun O, Nugent LF, Maminishkis A, Hinshaw SJ, Rodriguez IR, Gery I (2015) Inflammasomes induced by 7-ketocholesterol and other stimuli in RPE and in bone marrow-derived cells differ markedly in their production of IL-1β and IL-18. Invest Ophthalmol Vis Sci 56(3):1658–1664CrossRefGoogle Scholar
  42. 42.
    Piippo N, Korkmaz A, Hytti M, Kinnunen K, Salminen A, Atalay M, Kaarniranta K, Kauppinen A (2014) Decline in cellular clearance systems induces inflammasome signaling in human ARPE-19 cells. Biochim Biophys Acta 1843(12):3038–3046CrossRefGoogle Scholar
  43. 43.
    Bauernfeind F, Bartok E, Rieger A, Franchi L, Núñez G, Hornung V (2011) Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 187(2):613–617CrossRefGoogle Scholar
  44. 44.
    Sollberger G, Strittmatter GE, Kistowska M, French LE, Beer HD (2012) Caspase-4 is required for activation of inflammasomes. J Immunol 188(4):1992–2000CrossRefGoogle Scholar
  45. 45.
    Cheung KT, Sze DM, Chan KH, Leung PH (2018) Involvement of caspase-4 in IL-1β production and pyroptosis in human macrophages during dengue virus infection. Immunobiology 223(4–5):356–364CrossRefGoogle Scholar
  46. 46.
    Lugrin J, Martinon F (2018) The AIM2 inflammasome: sensor of pathogens and cellular perturbations. Immunol Rev 281(1):99–114CrossRefGoogle Scholar
  47. 47.
    Piippo N, Korhonen E, Hytti M, Kinnunen K, Kaarniranta K, Kauppinen A (2018) Oxidative stress is the principal contributor to inflammasome activation in retinal pigment epithelium cells with defunct proteasomes and autophagy. Cell Physiol Biochem 49(1):359–367CrossRefGoogle Scholar
  48. 48.
    Nicholas SA, Bubnov VV, Yasinska IM, Sumbayev VV (2011) Involvement of xanthine oxidase and hypoxia-inducible factor 1 in Toll-like receptor 7/8-mediated activation of caspase 1 and interleukin-1β. Cell Mol Life Sci 68(1):151–158CrossRefGoogle Scholar
  49. 49.
    Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O'Neill LA (2013) Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496(7444):238–242CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Fabian Doktor
    • 1
  • Philipp Prager
    • 1
  • Peter Wiedemann
    • 1
  • Leon Kohen
    • 1
    • 2
  • Andreas Bringmann
    • 1
  • Margrit Hollborn
    • 1
  1. 1.Department of Ophthalmology and Eye HospitalUniversity of LeipzigLeipzigGermany
  2. 2.Helios Klinikum AueAueGermany

Personalised recommendations